Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Amy Stutzman

Nurse Practitioner, Acute Care Wichita, KS Nurse Practitioner

NPI 1457709859 CMS profile 11233026

925 N Hillside St, Wichita, KS 67214

Open in the dashboard

General payments

$4,464

71 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Amy Stutzman of Wichita, KS is reported in the CMS Open Payments database as having received $4,464 across 71 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 93rd percentile of Nurse Practitioner, Acute Care profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $294 7
2024 General $2,708 26
2023 General $853 17
2022 General $98 6
2021 General $511 15

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Amy Stutzman
  • Nurse Practitioner, Acute Care median
  • Middle half of Nurse Practitioner, Acute Care
  • National median

In program year 2025, general payments to Amy Stutzman were reported at $294. Among 11,827 Nurse Practitioner, Acute Care profiles paid that year, the median was $152 and the middle half received between $48 and $458.

Show as a table
Year Amy Stutzman Nurse Practitioner, Acute Care median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $511 $123 $38–$327 $132
2022 $98 $130 $44–$369 $149
2023 $853 $144 $49–$410 $160
2024 $2,708 $146 $48–$433 $164
2025 $294 $152 $48–$458 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Medtronic, Inc. $3,862 48 payments
  2. Abbott Laboratories $246 9 payments
  3. ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $153 4 payments
  4. Boston Scientific Corporation $74 3 payments
  5. AstraZeneca Pharmaceuticals LP $51 3 payments
  6. Boehringer Ingelheim Pharmaceuticals, Inc. $33 2 payments
  7. Endologix, Inc. $25 1 payment
  8. CVRx, Inc. $20 1 payment

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $2,483 60 payments
  2. Travel and Lodging $1,981 11 payments
Products named General payments · program years 2021–2025
  1. Micra $538 14 payments
  2. LINQ II $457 8 payments
  3. LifeVest $153 4 payments
  4. ALLURE QUADRA $123 1 payment
  5. Cobalt $109 3 payments
  6. WATCHMAN FLX $37 1 payment
  7. AZURE XT DR MRI SURESCAN $37 3 payments
  8. Assurity Pacemaker $34 2 payments
  9. JARDIANCE $33 2 payments
  10. FARXIGA $31 2 payments
  11. Other $231 13 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 12 drugs

Part D claims

518

Median for Nurse Practitioner: 389

Drug cost

$102,524

Median for Nurse Practitioner: $21,885

Branded share of claims

48.5%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Brilinta Ticagrelor Brand 88 $46,230
Eliquis Apixaban Brand 52 $33,099
Xarelto Rivaroxaban Brand 17 $19,321
Flecainide Acetate Generic 75 $2,262
Clopidogrel Clopidogrel Bisulfate Brand 68 $584
Amiodarone Hcl Generic 73 $377
Pantoprazole Sodium Generic 30 $150
Sotalol Sotalol Hcl Brand 26 $127
Metoprolol Tartrate Generic 37 $125
Atorvastatin Calcium Generic 22 $108

The 10 drugs with the highest cost, of 12 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 9 billing codes

Paid by Medicare

$16,609

Medicare's payments for the services billed

Medicare patients

155

Average age 80

Services billed

221

74 women, 81 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Atrial fibrillation 70%
Ischemic heart disease 68%
Arthritis 61%
Heart failure 57%
Chronic kidney disease 48%
Diabetes 42%
Depression 41%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

71 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Acute Care in Kansas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record